Edition:
United States

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Capital Market

1.44USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$1.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
32,189
52-wk High
$3.69
52-wk Low
$1.03

Latest Key Developments (Source: Significant Developments)

Vical Reports Q2 Loss Per Share $0.22
Tuesday, 7 Aug 2018 06:30am EDT 

Aug 7 (Reuters) - Vical Inc ::VICAL REPORTS SECOND QUARTER 2018 FINANCIAL AND OPERATIONAL RESULTS.Q2 LOSS PER SHARE $0.22.Q2 REVENUE $700,000 VERSUS $3.4 MILLION.CASH AND INVESTMENTS OF $54.3 MILLION AT JUNE 30, 2018.ANTICIPATES ENDING 2018 WITH A MINIMUM OF $40 MILLION.VICAL - EXPECTS ENDING 2018 WITH MINIMUM $40 MILLION THAT WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH 2020.  Full Article

Vical Reports Q4 Loss Per Share Of $0.21
Thursday, 15 Mar 2018 06:30am EDT 

March 15 (Reuters) - Vical Inc ::VICAL REPORTS FOURTH QUARTER 2017 FINANCIAL AND OPERATIONAL RESULTS.Q4 LOSS PER SHARE $0.21.Q4 REVENUE $4.0 MILLION VERSUS $3.2 MILLION.‍PROJECTING NET CASH BURN FOR 2018 BETWEEN $20 MILLION AND $24 MILLION​.  Full Article

Astellas Says Cytomegalovirus Vaccine (ASP0113) Did Not Meet Its Primary Or Secondary Endpoints In Phase 3 Helios Clinical Trial​
Monday, 22 Jan 2018 03:00am EST 

Jan 22 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS AND VICAL ANNOUNCE TOP-LINE RESULTS FOR PHASE 3 TRIAL OF CYTOMEGALOVIRUS VACCINE ASP0113 IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.ASTELLAS PHARMA INC SAYS ‍VACCINE WAS GENERALLY WELL TOLERATED, WITH INJECTION-SITE REACTIONS BEING MOST COMMONLY REPORTED ADVERSE EVENT​.ASTELLAS PHARMA - ASP0113 DID NOT MEET ITS PRIMARY OR SECONDARY ENDPOINTS IN PHASE 3 HELIOS CLINICAL TRIAL​.  Full Article

‍Stonepine Capital Management reports 6.6 pct passive stake in Vical
Wednesday, 15 Nov 2017 06:12am EST 

Nov 15 (Reuters) - Vical Inc :‍Stonepine Capital Management Llc reports 6.6 percent passive stake in Vical Inc as on November 8, 2017 - SEC filing​.  Full Article

Vical Incorporated announces pricing of $25 mln underwritten public offering of common stock
Wednesday, 8 Nov 2017 06:30am EST 

Nov 8 (Reuters) - Vical Inc :Vical Incorporated announces pricing of $25 million underwritten public offering of common stock.Says public offering of 14.3 million common shares priced at $1.75per share.  Full Article

VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION
Tuesday, 24 Oct 2017 06:30am EDT 

Oct 24 (Reuters) - Vical Inc ::VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON A TREATMENT FOR CHRONIC HEPATITIS B INFECTION.‍INITIAL STAGE OF PROGRAM WILL BE TO DEMONSTRATE PRECLINICAL PROOF OF CONCEPT FOR INHIBITING HBV INFECTION IN HUMAN LIVER MODEL IN H2 2018​.‍ANGES HAS PROVIDED PARTIAL FUNDING FOR INITIAL STAGE OF PROGRAM​.‍IF INITIAL STAGE OF PROGRAM IS SUCCESSFUL, VICAL EXPECTS THAT ANGES WILL CONTINUE TO PARTICIPATE IN FUNDING OF PROGRAM ​.‍ANGES GRANTED RIGHT OF FIRST REFUSAL TO NEGOTIATE WITH CO FOR EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE HEPATITIS B THERAPY IN JAPAN​.  Full Article

Vical reports Q3 loss per share $0.27
Monday, 23 Oct 2017 06:30am EDT 

Oct 23 (Reuters) - Vical Inc :Vical reports third quarter 2017 financial and operational results.Q3 loss per share $0.27.Q3 revenue $3.2 million versus $2.6 million.  Full Article

Vical Inc files for common stock offering of up to $23.0 mln
Monday, 16 Oct 2017 05:00pm EDT 

Oct 16 (Reuters) - Vical Inc :Vical Inc files for common stock offering of up to $23.0 million - SEC filing‍​.  Full Article

Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial
Tuesday, 10 Oct 2017 06:30am EDT 

Oct 10 (Reuters) - Vical Inc :Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial.Vical Inc - ‍Astellas Pharma Inc. expects top-line data to be available in Q1 of 2018​.Vical Inc - continues to provide Astellas with development, regulatory and manufacturing support for program​.  Full Article

Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA
Monday, 2 Oct 2017 04:15pm EDT 

Oct 2 (Reuters) - Vical Inc :Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA based on a single phase 2 efficacy trial.Vical Inc - ‍plans to initiate phase 2 trial of VL-2397 for treatment of invasive Aspergillosis in 4Q 2017​.  Full Article

BRIEF-Vical Reports Q1 Loss Per Share $0.29

* VICAL REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATIONAL RESULTS